Zacks Research Decreases Earnings Estimates for Cytosorbents

Posted by on May 27th, 2026

Cytosorbents Corporation (NASDAQ:CTSO – Free Report) – Equities research analysts at Zacks Research reduced their FY2026 earnings per share estimates for shares of Cytosorbents in a research report issued on Thursday, May 21st. Zacks Research analyst T. Kerr now anticipates that the medical research company will earn ($0.20) per share for the year, down from their previous estimate of ($0.19). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.18) per share.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $8.86 million for the quarter, compared to analyst estimates of $9.40 million. Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.

Other analysts also recently issued reports about the company. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.38.

Read Our Latest Report on Cytosorbents

Cytosorbents Trading Up 0.4%

NASDAQ:CTSO opened at $0.46 on Wednesday. The stock has a 50-day simple moving average of $0.59 and a 200-day simple moving average of $0.66. The stock has a market cap of $29.05 million, a P/E ratio of -2.43 and a beta of 1.43. Cytosorbents has a 1 year low of $0.44 and a 1 year high of $1.39. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09.

Institutional Trading of Cytosorbents

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC raised its stake in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 36,790 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the last quarter. CM Management LLC raised its stake in Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after acquiring an additional 38,128 shares during the last quarter. Vanguard Group Inc. raised its stake in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cytosorbents during the 3rd quarter valued at approximately $105,000. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

(Get Free Report)

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.

Featured Articles

Earnings History and Estimates for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.